Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois/CHUV and University of Lausanne (UNIL), Lausanne, Switzerland.
Nestlé Research Center, Vevey, Switzerland.
Ann N Y Acad Sci. 2018 Dec;1434(1):84-93. doi: 10.1111/nyas.13731. Epub 2018 May 15.
Eosinophilic esophagitis (EoE) represents a chronic, local immune-mediated esophageal disease, characterized clinically by symptoms related to esophageal dysfunction and histologically by eosinophil-predominant inflammation. Other systemic and local causes of esophageal eosinophilia should be excluded. Clinical manifestations or pathologic data should not be interpreted in isolation. EoE was first described as a distinct disease entity in 1993. Most patients are diagnosed with underlying food allergies. The first diagnostic and therapeutic guidelines were published in 2007 with a first update in 2011. In 2017, new international guidelines were published based on the GRADE methodology. These guidelines provide, among many other topics, insights on the role of proton pump inhibitor-responsive esophageal eosinophilia. Over the last two decades, considerable progress was made by stakeholders regarding the understanding of EoE's pathogenesis, genetic background, natural history, allergy workup, standardization of assessment of disease activity, evaluation of minimally invasive diagnostic tools, and new therapeutic approaches. This brief review provides further insights into latest diagnostic and therapeutic advances.
嗜酸性粒细胞性食管炎(EoE)是一种慢性、局部免疫介导的食管疾病,临床上以与食管功能障碍相关的症状为特征,组织学上以嗜酸性粒细胞为主的炎症为特征。应排除其他引起食管嗜酸性粒细胞增多的全身和局部原因。临床表现或病理数据不应孤立解读。EoE 于 1993 年首次被描述为一种独特的疾病实体。大多数患者被诊断为潜在的食物过敏。第一个诊断和治疗指南于 2007 年发布,并于 2011 年进行了第一次更新。2017 年,基于 GRADE 方法学发布了新的国际指南。这些指南提供了许多其他主题的见解,包括质子泵抑制剂反应性食管嗜酸性粒细胞增多的作用。在过去的二十年中,利益相关者在 EoE 的发病机制、遗传背景、自然史、过敏检查、疾病活动评估的标准化、微创诊断工具的评估以及新的治疗方法方面取得了相当大的进展。这篇简短的综述进一步深入了解了最新的诊断和治疗进展。